GLYN122

GLYN122 is a preclinical-stage small molecule drug candidate being developed for the treatment of Huntington's disease. The asset is the result of a collaboration between NeuroBio.ai, which utilizes an artificial intelligence-driven drug discovery platform, and Galyan Bio. Huntington's disease is a fatal genetic neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin (HTT) gene, leading to the production of toxic mutant huntingtin protein (mHTT). GLYN122 is designed to intervene in the disease pathology, likely by targeting the neurotoxic effects or levels of mHTT. Based on the therapeutic focus of Galyan Bio, the molecule is intended to function as a neuroprotective agent that addresses the underlying cause of the disease, potentially through the inhibition of SIRT2 (Sirtuin 2), a protein whose modulation has shown promise in reducing mHTT aggregation and toxicity in neurodegenerative models.